TY  - JOUR
TI  - Single Center Experience on Screening Oncology Patients for Covid-19 Before Anti-Cancer Treatment
AB  - The most important factor in the transmission of the COVID-19 is asymptomatic carriers. We’ve tested all oncology patients , that receive anti-cancer therapy, for COVID-19. We aimed to determine the rate of asymptomatic carriers, and analyze the clinical and ra-diological findings of infected patients. Oncology patients who have indications of receiving anti-cancer treatment in the hospital were tested for COVID-19, two day prior to their treatment even if they were asymptomatic by collecting nasopharyngeal and oropharyngeal swab specimens for RT-PCR for viral RNA detection. Positive patients, underwent inspiratory phase of chest computed tomography examination. Infected patients were given the recommended treatment for COVID-19. PCR test was positive in 28 of 312 patients that we tested, and the positivity rate was 8.9%. Three patients (10.7%) had symptoms, 25 patients (89.3%) had no symptoms. Covid-19 testing before anti-cancer treatment may be recommended in order to continue their treatment without any problems and to prevent the risk of transmission due to the high rate of asymptomatics in infected patients.
AU  - OZTURK, Ali Vefa
AU  - ÇEVİK, Özkan Esin
AU  - YIR, Asiye
AU  - SABET, Soheyl
AU  - GURCAN, Nagihan Inan
AU  - namal, esat
AU  - DİNÇ, Merve Nur
AU  - Tokat, Yaman
AU  - ÇİFTÇİ, Cavlan
AU  - SOKMEN, Bedriye Koyuncu
AU  - SAGLAM, Sezer
AU  - DEMIR, Safiye Koculu
PY  - 2020
JO  - Uluslararası Hematoloji-Onkoloji Dergisi
VL  - 30
IS  - 4
SN  - 1306-133X
SP  - 207
EP  - 212
DB  - TRDizin
UR  - http://search/yayin/detay/419835
ER  -